Verrica Pharmaceuticals Inc. (VRCA) has announced promising preliminary results from Part 2 of its Phase 2 clinical trial investigating VP-315, a prospective first-in-class oncolytic peptide designed for the treatment of basal cell carcinoma (BCC). The company reported that all patients treated with VP-315 exhibited a reduction in tumor size, with an overall tumor size reduction of 86% across all subjects. Importantly, VP-315 demonstrated a favorable safety profile, with no treatment-related serious adverse events reported.
Ted White, CEO of Verrica Pharmaceuticals, expressed optimism, stating, "We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first-line therapy for both primary and neoadjuvant settings. We believe VP-315 has the potential to represent a multi-billion-dollar commercial opportunity for Verrica."
The company anticipates receiving genomic and T-cell data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA to discuss the subsequent development stages of VP-315 for BCC treatment in the first half of 2025.
Following the announcement, shares of Verrica Pharmaceuticals have surged 23% in pre-market trading on Wednesday.
